Investigational drug · Phase 2
ST266
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Necrotizing Enterocolitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
11
Any phase or sponsor naming "ST266"
First trial start
2024
Aug 19, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ST266", any sponsor or status.
Conditions studied
As listed on its trial records.
- Necrotizing Enterocolitis
Largest trials
Live from ClinicalTrials.gov: studies naming "ST266" as an intervention, largest first.
- Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe PeriodontitisPivotal-lookingCompleted
Noveome Biotherapeutics, formerly StemnionIndustry
NCT02761993 · 151 participants · Start Apr 2016 · Primary completion Oct 2017
Drug: ST266; Saline (0.9% NaCl) · For: Periodontal Disease
Sites: Birmingham, Alabama; Indianapolis, Indiana; Cambridge, Massachusetts · 6 sites in all
Noveome Biotherapeutics, formerly StemnionIndustry
NCT02978183 · 70 participants · Start Dec 2016 · Primary completion Feb 2017
Drug: ST266; Saline (0.9% NaCl) · For: Allergic Conjunctivitis
Sites: Andover, Massachusetts; Memphis, Tennessee
Noveome Biotherapeutics, formerly StemnionIndustry
NCT06315738 · 36 participants (planned) · Start Aug 19, 2024 · Primary completion Jun 2029
Drug: ST266 · For: Necrotizing Enterocolitis
Sites: Little Rock, Arkansas; New Haven, Connecticut; Tampa, Florida · 8 sites in all
Noveome Biotherapeutics, formerly StemnionIndustry
NCT02369861 · 30 participants · Start Mar 2015 · Primary completion Oct 2015
Drug: ST266; Refresh Lubricant Eye Drops · For: Dry Eye Syndrome
Sites: Indianapolis, Indiana
Noveome Biotherapeutics, formerly StemnionIndustry
NCT01714973 · 20 participants · Start Oct 2012 · Primary completion Jul 2015
Drug: ST266 · For: Radiation-induced Dermatitis
Sites: Pittsburgh, Pennsylvania
Noveome Biotherapeutics, formerly StemnionIndustry
NCT00886470 · 16 participants · Start Jun 2009 · Primary completion Mar 2010
Drug: ST266 · For: Burns
Sites: Mobile, Alabama; Los Angeles, California; Gainesville, Florida · 14 sites in all
Noveome Biotherapeutics, formerly StemnionIndustry
NCT03687632 · 13 participants · Start Jun 10, 2019 · Primary completion Aug 18, 2020
Drug: ST266 · For: Persistent Corneal Epithelial Defect
Sites: Indianapolis, Indiana; Edgewood, Kentucky; Baltimore, Maryland · 8 sites in all
Noveome Biotherapeutics, formerly StemnionIndustry
NCT04720378 · 12 participants · Start May 30, 2021 · Primary completion May 3, 2022
Drug: ST266 · For: Cytokine Release Syndrome
Sites: Clearwater, Florida; Chicago, Illinois; Chattanooga, Tennessee
- ST266 in UV-induced InflammationCompleted
Noveome Biotherapeutics, formerly StemnionIndustry
NCT02389777 · 10 participants · Start Mar 2015 · Primary completion Aug 2015
Drug: ST266 immediate; ST266 delayed · For: Skin Burns
Noveome Biotherapeutics, formerly StemnionIndustry
NCT05066698 · 8 participants · Start Apr 27, 2022 · Primary completion Sep 7, 2022
Drug: ST266; Open-label ST266 · For: Persistent Corneal Epithelial Defect
Sites: Dothan, Alabama; Little Rock, Arkansas; Huntington Beach, California · 31 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Natural occurrence of a slow lytic pseudomonas phage in a Pediatric case of multidrug-resistant P. aeruginosa severe pneumonia.
Sun J, Zhou J, Wang L, et al. · Virus Genes 2026
- Emergence of cefiderocol resistance mediated by blaAFM-1 overexpression and FptA mutations in clinical carbapenem-resistant Pseudomonas aeruginosa isolates.
Xiao Y, Zhang J, Nie F, et al. · Clin Microbiol Infect 2026
- Prophylactic treatment with amnion progenitor cell secretome mitigates traumatic optic neuropathy.
Browning M, McCartan R, Gratkowski A, et al. · Exp Eye Res 2025
- Genetic variability of Staphylococcus Pseudintermedius in animals from Mato Grosso, Brazil: methicillin-resistant clonal complexes and discovery of new sequence types.
da Silva Alves A, Maruyama FH, de Lima Ruy Dias ÁF, et al. · Vet Res Commun 2025
- Melioidosis in goats at a single Australian farm was caused by multiple diverse lineages of Burkholderia pseudomallei present in soil.
Busch JD, Kaestli M, Mayo M, et al. · PLoS Negl Trop Dis 2024
- The novel secretome ST266 activates Akt and protects against oxidative stress-mediated injury in human RPE and Müller cells.
Tang AC, Besley NA, Trimpey-Warfhatig R, et al. · Exp Eye Res 2024
Also in development for Necrotizing Enterocolitis
- IBP-9414Phase 31 trial
Infant Bacterial Therapeutics · Necrotizing Enterocolitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.